ARCHIVES

NCI-Approved Clinical Trials

This article is from The Cancer Letter archive.

Vol. 28 No. 7 | July 29, 2005

Download PDF Visit The Full Archive

Related Articles

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

Kidney, Bladder Cancer Causes, Treatment, Need More Research, NCI Advisors Find

July 26, 2002

ODAC Member Critical Of Amgen For Price Incentives.

March 21, 2008

GAO Report Refutes Charges Against Control Program

May 30, 1980

NCAB Subcommittee Approves Concept Of Qualifying Minimums, Salary Support Limit For Core Grants

October 3, 1980

Beckman Coulter Offers Immunoassay System.

July 27, 2001